These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32745456)

  • 1. Pharmacotherapy for the Treatment of Cannabis Use Disorder.
    Brezing CA; Levin FR
    Ann Intern Med; 2020 Aug; 173(3):247-248. PubMed ID: 32745456
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacotherapy for the Treatment of Cannabis Use Disorder.
    Kansagara D; Kondo KK; Morasco BJ; Nugent SM; Ayers CK
    Ann Intern Med; 2020 Aug; 173(3):248-249. PubMed ID: 32745455
    [No Abstract]   [Full Text] [Related]  

  • 3. Cannabis Use Disorder in Adolescence.
    Simpson AK; Magid V
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):431-43. PubMed ID: 27338965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When and How to Treat Possible Cannabis Use Disorder.
    Lévesque A; Le Foll B
    Med Clin North Am; 2018 Jul; 102(4):667-681. PubMed ID: 29933822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review.
    Baker AL; Hides L; Lubman DI
    J Clin Psychiatry; 2010 Mar; 71(3):247-54. PubMed ID: 20331929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents.
    Nielsen S; Sabioni P; Gowing L; Le Foll B
    Handb Exp Pharmacol; 2020; 258():355-372. PubMed ID: 31375922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cannabis use disorder and treatment of dependence].
    Morioka N; Kohda H; Nakata Y
    Nihon Rinsho; 2010 Aug; 68(8):1475-8. PubMed ID: 20715479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Cannabis Use Disorder: Current Science and Future Outlook.
    Sherman BJ; McRae-Clark AL
    Pharmacotherapy; 2016 May; 36(5):511-35. PubMed ID: 27027272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.
    McClure EA; Baker NL; Sonne SC; Ghitza UE; Tomko RL; Montgomery L; Babalonis S; Terry GE; Gray KM
    Drug Alcohol Depend; 2018 Nov; 192():59-66. PubMed ID: 30218864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency.
    Makkos Z; Fejes L; Inczédy-Farkas G; Kassai-Farkas A; Faludi G; Lazary J
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):212-7. PubMed ID: 21087649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
    Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
    Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.
    Schipper R; Dekker M; de Haan L; van den Brink W
    J Psychopharmacol; 2018 Mar; 32(3):353-356. PubMed ID: 29039260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review.
    Kondo KK; Morasco BJ; Nugent SM; Ayers CK; O'Neil ME; Freeman M; Kansagara D
    Ann Intern Med; 2020 Mar; 172(6):398-412. PubMed ID: 32120384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.
    Brezing CA; Levin FR
    Neuropsychopharmacology; 2018 Jan; 43(1):173-194. PubMed ID: 28875989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cannabis: Use and dependence].
    Dervaux A; Laqueille X
    Presse Med; 2012 Dec; 41(12 Pt 1):1233-40. PubMed ID: 23040955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nabiximols as a substitute for cannabis].
    Dumont GJH
    Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33201625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
    Makkos Z; Fejes L; Inczédy-Farkas G; Kassai-Farkas A; Faludi G; Lazáry J
    Neuropsychopharmacol Hung; 2011 Sep; 13(3):127-38. PubMed ID: 21876221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cannabis use disorders].
    Bonnet U; Scherbaum N
    Fortschr Neurol Psychiatr; 2010 May; 78(5):297-302; quiz 303-5. PubMed ID: 20309787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.